Simpkins Lab

Selected Publications

1. Simpkins F, Armstrong D, Zahurak M, Grumbine F, Bristow R: Ovarian malignancy in breast cancer patients with an adnexal mass. Obstet Gynecol 105(3):507-13, Mar 2005.
2. Kamrava M, Simpkins F, Alejandro E, Michener C, Meltzer E, Kohn E: Lysophosphatidic Acid and Endothelin-induced proliferation of ovarian cancer cell lines is mitigated by neutralization of granulin-epithelin precursor (GEP), a prosurvival factor in ovarian cancer. Oncogene 24(47):7084-93, Oct 2005.
3. Simpkins F, Belinson JL, Rose PG: Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol 107(1):118-23, Oct 2007.
4. Simpkins F, Kamrava M, Devoogdt N, Tchabo N, Alejandro E, Kohn E: The alarm anti-protease, secretory leukocyte protease inhibitor is a proliferation and survival factor for ovarian cancer cells. Carcinogenesis 29(3):466-72, Mar 2008.
5. Kunos C, Simpkins F, Gibbons H, Tian C, Homesley H: Radiation Therapy Compared With Pelvic Node Resection for Node-Positive Vulvar Cancer: A Randomized Controlled Trial. Obstet Gynecol 114(3):537-546, Sep 2009.
6. Simpkins F, Hevia-Perez P, Sun J, Ullmer W, Gilbert CA, da Silva T, Pedram A, Levine ER, Reis IM, Rabinovich B, Azzam D, Xu XX, Ince TA, Yang JY, Verhaak RG, Lu Y, Mills GB, Slingerland JM: Src inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. Clin Cancer Res 18(21):5911-23, Nov 2012.
7. Simpkins F, Papadia A, Kunos C, Michener C, Frasure H, AbuShahin F, Mariani A, Bakkum-Gamez JN, Landrum L, Moore K, Thomas SG, Windhorn A, Rose PG: Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphovascular space invasion. Int J of Gynecol Cancer 23(1):98-104, Jan 2013.
8. Simpkins F, Flores A, Chu C, Berek JS, Lucci J 3rd, Murray S, Bauman J, Struemper H, Germaschewski F, Jonak Z, Gardner O, Toso J, Coukos G: Chemoimmunotherapy using pegylated liposomal Doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation study. Cancer Immunol Res 1(3):168-78, Sep 2013.
9. Simpkins F, Drake R, Escobar PF, Nutter B, Rasool N2, Rose PG: A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA). Gynecol Oncol 136(2):240-5, Feb 2015.
10. Hew KE, Miller PC, El-Ashry D, Sun J, Besser AH, Ince TA, Gu M, Wei Z, Zhang G, Brafford P, Gao W, Lu Y, Mills GB, Slingerland JM, Simpkins F: MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer. Clin Cancer Res 22(4):935-47, Feb 2016.
11. Wang Y, Krais JJ, Bernhardy AJ, Nicolas E, Cai KQ, Harrell MI, Kim HH, George E, Swisher EM, Simpkins F, Johnson N: RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance. J Clin Invest 1;126(8):3145-57, Aug 2016.
12. George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, Zhang X, Soslow R, Drapkin R, Johnson N, Zheng Y, Cotsarelis G, Nathanson KL, Simpkins F: A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. JCI Insight 2(1):e89760 (doi: 10.1172/jci.insight.89760), Jan 2017.
13. Rose PG, Ali S, Moslemi-Kebria M, Simpkins F: Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma. Int J Gynecol Cancer 27(3):452-458, Mar 2017.
14. Garcia-Soto AE, Schreiber T, Strbo N, Ganjei-Azar P, Miao F, Koru-Sengul T, Simpkins F, Nieves-Neira W, Lucci J 3rd, Podack ER: Cancer-testis antigen expression is shared between epithelial ovarian cancer tumors. Gynecol Oncol 145(3):413-419, Jun 2017.
15. Kim H, George E, Ragland RL, Rafail S, Zhang R, Krepler C, Morgan M, Herlyn M, Brown EJ, Simpkins F: Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA mutant ovarian cancer models. Clin Cancer Res 23(12):3097-3108, Jun 2017.
16. Karakashev S, Zhu H, Yokoyama Y, Zhao B, Fatkhutdinov N, Kossenkov AV, Wilson AJ, Simpkins F, Speicher D, Khabele D, Bitler BG, Zhang R: BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer. Cell Reports  21(12):3398-3405, Dec 2017.
17. Simpkins F, Jang K, Yoon H, Hew K, Kim M, Azzam D, Sun J, Zhao D, Ince, T, Liu W, Guo W, Zhi Wei, Zhang G, Mills G, *Slingerland JM. *Co-corresponding authors. Dual Src and MEK inhibition decreases ovarian cancer growth and targets tumor initiating stem-like cells. Clin Cancer Res, accepted with revisions Feb, 2018.
18. Makvandi, M, Pantel A, Schwartz L, Schubert E, Xu K, Hsieh CJ, Hou C, Kim H, Weng CC, Winters H, Doot R, Farwell MD, Pryma DA, Greenberg RA, Mankoff DA, Simpkins F, Mach B, Lin L. A PET imaging agent for evaluating PARP-1 expression in ovarian cancer. Journal of Clinical Investigation, March, 2018, in press.